- Trial phase
- Phase 3
- Time to market
- Estimated at 2-4 years assuming successful completion of the ongoing Phase 3 trials, regulatory filing, and FDA review.
- Why 5/10
- GB-0895 is GENB's lead and only Phase 3 asset, but the SOLAIRIA-1 and SOLAIRIA-2 Phase 3 trials are still recruiting (announced as of Q3 2026) with no disclosed topline readout date within the next ~12 months, so no hard dated binary catalyst is currently visible.
GB-0895 is the lead asset driving essentially all of GENB's valuation. Watch for updates on SOLAIRIA-1 and SOLAIRIA-2 enrollment completion and any disclosed Phase 3 topline timeline, as that will be the next major binary event. Also monitor Tezspire's (tezepelumab) commercial trajectory and label expansion, as it is the direct competitor and its performance sets market expectations for TSLP-targeting therapies. The Zealand Pharma partnership provides non-dilutive cash but is early-stage and adds no near-term revenue.
Price Chart
Executive Summary
GB-0895 (golukibart) is Generate Biomedicines' lead drug candidate: an AI-designed anti-TSLP monoclonal antibody for severe asthma, currently in two global Phase 3 trials (SOLAIRIA-1 and SOLAIRIA-2) that are recruiting approximately 1,600 patients. Its key differentiator is ultra-long-acting pharmacokinetics enabling twice-yearly subcutaneous dosing, versus the market-leading anti-TSLP Tezspire (tezepelumab from Amgen/AstraZeneca) which requires monthly injections. Phase 1 data showed a single dose suppressed asthma-related biomarkers for six months. The company raised $400M in an IPO in early 2026 and held $404.2M in cash as of Q3 2026, with runway into H1 2028. The company is largely a single-asset story for the near term, as the rest of the pipeline (GB-5267 CAR-T, GB-4362 MMAE neutralizer) is at Phase 1 or preclinical. GB-0895 is also being explored in COPD (Phase 1b data presented at ERS 2026).
How It Works
GB-0895 is a monoclonal antibody (a lab-made protein that mimics the immune system's ability to fight unwanted substances) designed to block TSLP (Thymic Stromal Lymphopoietin), a protein that sits at the top of the inflammatory cascade in asthma and triggers a wide range of allergic and inflammatory responses. By neutralizing TSLP, GB-0895 aims to reduce airway inflammation across many asthma subtypes, regardless of specific blood markers. It was engineered using Generate's AI-based generative biology platform to have an ultra-long duration of action, enabling twice-yearly (every 6 months) dosing.
Trial Status
Two global Phase 3 trials (SOLAIRIA-1 and SOLAIRIA-2) evaluating GB-0895 for twice-yearly dosing in ~1,600 adults and adolescents with severe asthma. Recruitment was underway across all six global regions as of Q2/Q3 2026. Phase 1b data in COPD was presented at the European Respiratory Society (ERS) Congress in September 2026.
The Two-Sided Case
Upcoming Catalysts
- Completion of enrollment in SOLAIRIA-1 and SOLAIRIA-2 Phase 3 trials (no disclosed timeline)
- Phase 3 topline data readout (no disclosed timeline)
- Potential further COPD data updates
- Updates from the Zealand Pharma obesity collaboration
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Generate Biomedicines, Inc. 8-K GENB ·Originating report